Korea FDA Gears Up To Release Biosimilar Guidelines Modeled After EU Rules
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's FDA is getting ready to release - possibly by the end of May - an initial version of guidelines for approval and registration of biosimilars modeled after European Union rules. The guidelines will wrap up KFDA's year-long drive to set up a regulatory framework for the new breed of follow-on biologics
You may also be interested in...
Korea's Celltrion Develops Universal "Super Flu-Antibody Therapy"
SEOUL - South Korean biopharma company Celltrion has developed a human monoclonal antibody product that could be effective against multiple influenza viruses such as the pandemic H1N1 and the H5N1 avian influenza virus
Korea's Celltrion Develops Universal "Super Flu-Antibody Therapy"
SEOUL - South Korean biopharma company Celltrion has developed a human monoclonal antibody product that could be effective against multiple influenza viruses such as the pandemic H1N1 and the H5N1 avian influenza virus
New Pricing System Could Deal A Blow To South Korea's Generic-Dependent Companies
SEOUL - As part of its effort to root out illegal rebates, the Ministry for Health, Welfare and Family Affairs said it would launch a new "drug-pricing system" in October aimed at compensating hospitals that buy drugs at lower prices than their government-set maximum prices